Welcome to our dedicated page for DiagnaMed Holdings news (Ticker: DGNMF), a resource for investors and traders seeking the latest updates and insights on DiagnaMed Holdings stock.
DiagnaMed Holdings Corp. reports company developments tied to its role as a Canadian technology company serving clean tech and life sciences markets, with recent updates centered on natural hydrogen initiatives. News commonly covers hydrogen extraction technology, soil-gas survey results in Ontario's Témiscamingue Graben, collaboration with Québec Innovative Materials Corp. and INRS, and agreements related to natural hydrogen development in the Ontario-Québec corridor. Other recurring updates address leadership changes, equity-incentive grants, shareholder voting matters, governance and capital-structure disclosures.
DiagnaMed Holdings Corp., a healthcare technology firm focused on brain health using AI, has announced a private placement offering of up to $650,000. This offering, led by EMD Financial, is priced at $0.04 per unit. Each unit consists of one common share and one warrant, allowing acquisition of an additional share at $0.05 within 36 months. The proceeds will fund the BRAIN AGE® Brain Health AI Platform and general purposes. The offering is open to most Canadian provinces and closes around June 10, 2024, pending regulatory approvals.
DiagnaMed Holdings Corp. is set to commercialize its BRAIN AGE® Brain Health AI Platform, an innovative solution that estimates brain age and provides a brain health score.
This platform aims to target the global digital brain health market, projected to reach USD 405.53 billion by 2031. BRAIN AGE® assesses brain health using a low-cost EEG headset and a proprietary machine-learning model, making it accessible and affordable for large-scale use.
The platform is clinically validated through studies at Drexel University and the University of Miami, showing its potential in detecting cognitive decline and optimizing brain performance.
BRAIN AGE® targets diverse users, including healthy individuals, athletes, and neurodegenerative patients, with potential applications in up to 10,000 North American clinics. The platform's goal is to empower individuals and healthcare professionals to improve brain health through personalized diagnostics and interventions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.